Mateos, Maria-Victoria; Nahi, Hareth; Legiec, Wojciech; Grosicki, Sebastian; Vorobyev, Vladimir; Spicka, Ivan; Hungria, Vania; Korenkova, Sibirina; Bahlis, Nizar; Flogegard, Max; Bladé, Joan; Moreau, Philippe; Kaiser, Martin; Iida, Shinsuke; Laubach, Jacob; Magen, Hila; Cavo, Michele; Hulin, Cyrille; White, Darrell; De Stefano, Valerio; Clemens, Pamela L; Masterson, Tara; Lantz, Kristen; O'Rourke, Lisa; Heuck, Christoph; Qin, Xiang; Parasrampuria, Dolly A; Yuan, Zhilong; Xu, Steven; Qi, Ming; Usmani, Saad Z . (2020). Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. The Lancet Haematology, 7(5), e370–e380.
doi:10.1016/S2352-3026(20)30070-3
